Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- The subject must be covered by a social security system
- Eligible for PET-CT
- Untreated stage B or C chronic lymphocytic leukemia
- ...
- The subject must be covered by a social security system
- Eligible for PET-CT
- Untreated stage B or C chronic lymphocytic leukemia
- Untreated diffuse large B-cell lymphoma
- Signed written informed consent
- Adult over 18
Exclusion Criteria
- corticosteroid therapy
- Patients concurrently included in an investigational trial
- active infectious disease
- ...
- corticosteroid therapy
- Patients concurrently included in an investigational trial
- active infectious disease
- patients with creatinine clearance < 30 ml/mn
- pregnant women
- Age under 18
- Weight over 120 kg
- immune hemolytic anemia
Summary
- Conditions
- Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- The subject must be covered by a social security system
- Eligible for PET-CT
- Untreated stage B or C chronic lymphocytic leukemia
- ...
- The subject must be covered by a social security system
- Eligible for PET-CT
- Untreated stage B or C chronic lymphocytic leukemia
- Untreated diffuse large B-cell lymphoma
- Signed written informed consent
- Adult over 18
Exclusion Criteria
- corticosteroid therapy
- Patients concurrently included in an investigational trial
- active infectious disease
- ...
- corticosteroid therapy
- Patients concurrently included in an investigational trial
- active infectious disease
- patients with creatinine clearance < 30 ml/mn
- pregnant women
- Age under 18
- Weight over 120 kg
- immune hemolytic anemia
Tracking Information
- NCT #
- NCT02128945
- Collaborators
- CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France
- Investigators
- Principal Investigator: Sylvain P CHANTEPIE, MD University Hospital, Caen
- Sylvain P CHANTEPIE, MD University Hospital, Caen
Get Well Soon